Premium
The future of blood‐based biomarkers for Alzheimer's disease
Author(s) -
Henriksen Kim,
O'Bryant Sid E.,
Hampel Harald,
Trojanowski John Q.,
Montine Thomas J.,
Jeromin Andreas,
Blennow Kaj,
Lönneborg Anders,
WyssCoray Tony,
Soares Holly,
Bazenet Chantal,
Sjögren Magnus,
Hu William,
Lovestone Simon,
Karsdal Morten A.,
Weiner Michael W.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.01.013
Subject(s) - disease , biomarker , medicine , intensive care medicine , population , alzheimer's disease , bioinformatics , biology , biochemistry , environmental health
Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability. With these aspects in mind, the aim of this article is to underscore the concerted efforts of the Blood‐Based Biomarker Interest Group, an international working group of experts in the field. The points addressed include: (1) the major challenges in the development of blood‐based biomarkers of AD, including patient heterogeneity, inclusion of the “right” control population, and the blood–brain barrier; (2) the need for a clear definition of the purpose of the individual markers (e.g., prognostic, diagnostic, or monitoring therapeutic efficacy); (3) a critical evaluation of the ongoing biomarker approaches; and (4) highlighting the need for standardization of preanalytical variables and analytical methodologies used by the field.